# Sample Selection

Filter the overall sample list that survival analysis is conducted for by received treatments and the status of clinical biomarkers.  

### Treatment Group

Select a subgroup of patient samples treated with a specific combination three treatment regimens: endocrine therapy (Endo, e.g. tamoxifen),  chemo therapy (Chemo), and anti HER2 therapy (HER2, e.g. trastuzumab). Available treatment combinations:

- Any
- Endocrine + any
- Chemo + any
- HER2 + any
- Endocrine only
- Chemo only
- HER2 only
- Endo + Chemo + any
- Endo + HER2 + any
- Cyto + HER2 + any
- Endo + Chemo only
- Endo + HER2 only
- Cyto + HER2 only
- Endo + Chemo + HER2
- No Systemic Treatment


### Biomarkers

| Biomarker         | Description                                                                     |
|:----------------- |:------------------------------------------------------------------------------- |
| ER                | Estrogen receptor; Positive for >0% IHC staining cells, otherwise Negative)     |
| PgR               | Progesterone receptor; Positive for >0% IHC staining cells, otherwise Negative) |
| HER2              | Epidermal growth factor receptor 2 (HER2/ERBB2)                                 |
| Ki67              | Ki67 progression marker (staining cutoffs varying)                              |
| NHG               | Nottingham histological grade                                                   |
| PAM50             | Intrinsic breast cancer subtype based on the PAM50 gene list                    |
